other material
confidence high
sentiment positive
materiality 0.60
Taysha Gene Therapies gets IDMC nod to continue REVEAL Phase 1/2 trial for TSHA-102 in Rett syndrome
Taysha Gene Therapies, Inc.
- IDMC recommended trial continuation after review of initial clinical data from first adult dosed with TSHA-102.
- Dosing of second patient expected in Q3 2023.
- Initial clinical update on first patient planned for Q2 2023 earnings call in mid-August.
- TSHA-102 is an AAV-based gene therapy for Rett syndrome due to MECP2 loss-of-function mutation.